LONDON (Alliance News) - GlaxoSmithKline PLC's ViiV Healthcare joint venture on Thursday said it has formalised its collaboration agreement with Janssen Sciences Ireland for the phase 3 investigation and commercialisation of respective HIV-1 treatments.
The collaboration will study formulations of ViiV's cabotegravir and Janssen's rilpivirine. Janssen is a subsidiary of US healthcare giant Johnson & Johnson Inc.
"As a company committed to innovation in the field of HIV, this agreement with Janssen will enable us to progress the development of the first long-acting, injectable two-drug regimen," said Dominique Limet, the chief executive of ViiV Healthcare.
"If successful, this regimen would offer people living with HIV who have achieved viral suppression an alternative option to the standard oral daily, three-drug therapy," Limet added.
Glaxo shares were down 3.2% to 1,336.34 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.